Navigation Links
St. Jude Scientist Named Pew Scholar
Date:6/16/2009

Charles Mullighan, M.D., Ph.D., becomes fourth St. Jude scientist honored

MEMPHIS, Tenn., June 16 /PRNewswire-USNewswire/ -- Charles Mullighan, M.D., Ph.D., an assistant member in the Pathology Department at St. Jude Children's Research Hospital, has been named a 2009 Pew Scholar in the Biomedical Sciences.

Selected by The Pew Charitable Trusts as one of 17 of the country's most promising early-career scientists, Mullighan will receive a $240,000 award over four years to support his research.

"Dr. Mullighan's appointment as a Pew Scholar is further validation of his remarkable accomplishments at this early stage in his career and the potential he has as a physician-scientist to make major discoveries in the future," said Dr. William E. Evans, St. Jude director and CEO. "We are fortunate to have Dr. Mullighan as one of a strong group of junior faculty who ensure the future success of St. Jude."

Mullighan's research focuses on the use of high-resolution, genome-wide approaches to identify genomic aberrations contributing to leukemogenesis and influencing leukemia outcome; the use of in vitro and in vivo experimental approaches to model genomic abnormalities in leukemogenesis; and the genetics of disease susceptibility and disease phenotype, most notably the genetic determinants of allogeneic hematopoietic stem cell transplant outcome.

"Being named a Pew Scholar is a tremendous honor and will provide very important support at this stage of my career," Mullighan said. "The award also reflects the exceptional research environment at St. Jude that has enabled the work recognized by the scholarship to be performed."

Pew Scholars are junior faculty members at medical schools and research institutions who show outstanding promise in research that is related to the advancement of human health.

A native of Adelaide, Australia, Mullighan attended medical school at the University of Adelaide, earning a Bachelor of Medicine and Bachelor of Surgery with honors in 1993. He received a Master of Science from the University of London in 1997; and earned a Doctor of Medicine from the University of Adelaide in 1998.

Mullighan is a fellow of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia. In 2004, he joined the staff at St. Jude as a postdoctoral fellow in Pathology and was named an assistant member in the department in May 2008. Mullighan is also the recipient of the prestigious American Society of Hematology Merit and Scholar awards.

Brenda Schulman, Ph.D., a member of Structural Biology and Genetics/Tumor Cell Biology at St. Jude, became the hospital's first Pew Scholar in 2002. Michael Dyer, Ph.D., a member of Developmental Neurobiology at St. Jude, received the distinction in 2004, and Joseph Opferman, Ph.D., an assistant member of Biochemistry, was honored in 2006.

In its 25th year, the Pew Scholars Program in the Biomedical Sciences has invested more than $125 million to support more than 460 scholars. Previous scholars have gone on to win the Nobel Prize, MacArthur Award Fellowships and the Albert Lasker Medical Research Award.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fundraising organization. For more information, please visit www.stjude.org.


'/>"/>
SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
2. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
3. Scientists advance safety of nanotechnology
4. UNC scientists identify growth factor as possible cancer drug target
5. World first: Chinese scientists create pig stem cells
6. Scientists use bed bugs own chemistry against them
7. NYP/Weill Cornell physician-scientists present at 2009 American Transplant Congress in Boston
8. Scripps Florida scientists devise accelerated method to determine infectious prion strains
9. Berkeley Lab scientist co-leads breast cancer dream team
10. Scientists find city rats are loyal to their hoods
11. Scientists find shared genetic link between the dental disease periodontitis and heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/19/2017)... 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, ... three leadership team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has ...
Breaking Medicine Technology: